Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Francesca R. Mauro, Stefano Molica, Luca Laurenti, Agostino Cortelezzi, Angelo M. Carella, Francesco Zaja, Annalisa Chiarenza, Francesco Angrilli, Francesco Nobile, Roberto Marasca, Caterina Musolino, Maura Brugiatelli, Alfonso Piciocchi, Marco Vignetti, Paola Fazi, Giuseppe Gentile, Maria S. De Propris, Irene Della Starza, Marilisa Marinelli, Sabina ChiarettiIlaria Del Giudice, Mauro Nanni, Francesco Albano, Antonio Cuneo, Anna Guarini, Robin Foà

Research output: Contribution to journalArticle

Abstract

In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab®) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.

Original languageEnglish
Pages (from-to)198-203
Number of pages6
JournalLeukemia Research
Volume38
Issue number2
DOIs
Publication statusPublished - Feb 2014

    Fingerprint

Keywords

  • Alemtuzumab
  • Biology
  • Chronic lymphocytic leukemia
  • CLL
  • Fludarabine
  • Young

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology
  • Medicine(all)

Cite this

Mauro, F. R., Molica, S., Laurenti, L., Cortelezzi, A., Carella, A. M., Zaja, F., Chiarenza, A., Angrilli, F., Nobile, F., Marasca, R., Musolino, C., Brugiatelli, M., Piciocchi, A., Vignetti, M., Fazi, P., Gentile, G., De Propris, M. S., Starza, I. D., Marinelli, M., ... Foà, R. (2014). Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. Leukemia Research, 38(2), 198-203. https://doi.org/10.1016/j.leukres.2013.11.009